TABLE 2.
Results of the two-dose NaB-PBS treatment regimen administered over a 48-h perioda
| Virus strain | Treatment on day:
|
No. of positive swabs/total no. of swabs (%) | No. of positive TG/total no. of TG (%) | No. of surviving mice/total no. of mice (%) | |
|---|---|---|---|---|---|
| 1 | 2 | ||||
| McKrae | 1,200-mg/kg dose of NaB in PBS | 600-mg/kg dose of NaB in PBS | 15/28 (54) | 8/8 (100) | 4/7 (57) |
| PBS alone | PBS alone | 0/24 (0) | 0/8 (0) | 4/4 (100) | |
| dLAT2903 | 1,200-mg/kg dose of NaB in PBS | 600-mg/kg dose of NaB in PBS | 0/30 (0) | 0/8 (0) | 4/8 (50) |
| PBS alone | PBS alone | 0/24 (0) | 0/8 (0) | 4/4 (100) | |
a
The regimen consisted of a 1,200-mg/kg dose of NaB in PBS given intraperitoneally on day 28 postinoculation, followed by a 600-mg/kg dose of NaB in PBS administered 24 h later, on day 29 postinoculation. Mice were assayed via eye swabbing for the presence of infectious virus in the eyes for three consecutive days. The swab data provided are cumulative for all swabs taken, but the presence of infectious virus was detected as early as 24 h posttreatment. All mice were sacrificed at 72 h after the first injection of NaB-PBS or PBS alone, and the TG were removed and homogenized. The supernatant was plated onto PRK cells and observed for CPE.